GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neos Therapeutics Inc (NAS:NEOS) » Definitions » EPS without NRI

Neos Therapeutics (Neos Therapeutics) EPS without NRI : $-0.44 (TTM As of Sep. 2020)


View and export this data going back to 2015. Start your Free Trial

What is Neos Therapeutics EPS without NRI?

Neos Therapeutics's earnings per share without non-recurring items for the three months ended in Sep. 2020 was $-0.10. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2020 was $-0.44.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 60.30% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 27.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Neos Therapeutics's EPS without NRI or its related term are showing as below:

NEOS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -62.9   Med: 5.5   Max: 60.3
Current: 60.3

During the past 7 years, Neos Therapeutics's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 60.30% per year. The lowest was -62.90% per year. And the median was 5.50% per year.

NEOS's 3-Year EPS without NRI Growth Rate is not ranked
in the Drug Manufacturers industry.
Industry Median: 9.2 vs NEOS: 60.30

Neos Therapeutics's EPS (Diluted) for the three months ended in Sep. 2020 was $-0.10. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2020 was $-0.44.

Neos Therapeutics's EPS (Basic) for the three months ended in Sep. 2020 was $-0.10. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2020 was $-0.44.


Neos Therapeutics EPS without NRI Historical Data

The historical data trend for Neos Therapeutics's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neos Therapeutics EPS without NRI Chart

Neos Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
EPS without NRI
Get a 7-Day Free Trial -4.38 -5.16 -2.66 -1.60 -0.34

Neos Therapeutics Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 -0.07 -0.16 -0.11 -0.10

Competitive Comparison of Neos Therapeutics's EPS without NRI

For the Drug Manufacturers - Specialty & Generic subindustry, Neos Therapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neos Therapeutics's PE Ratio without NRI Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neos Therapeutics's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Neos Therapeutics's PE Ratio without NRI falls into.



Neos Therapeutics EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neos Therapeutics  (NAS:NEOS) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Neos Therapeutics EPS without NRI Related Terms

Thank you for viewing the detailed overview of Neos Therapeutics's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Neos Therapeutics (Neos Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
2940 N. Highway 360, Grand Prairie, TX, USA, 75050
Neos Therapeutics Inc is a pharmaceutical company, engaged in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technologies. The product portfolio of the company includes Methylphenidate XR-ODT and Amphetamine XR oral suspension commonly prescribed medicine for the treatment of ADHD. In addition, it also manufactures and markets generic Tussionex, a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension product indicated for the relief of cough. Geographically, it operates through the United States and derives revenue through the sale of products.
Executives
Alan L Heller director BAXTER INTERNATIONAL INC ONE BAXTER PKWY DF2-2W DEERFIELD IL 60015
Gregory J Robitaille director
John P. Schmid director 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Beth Hecht director C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 360, GRAND PRAIRIE TX 75050
Linda M Szyper director C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 250, SUITE 400, GRAND PRAIRIE TX 75050
Bryant Fong director 2170 VALLEJO STREET #101, SAN FRANCISCO CA 94123
Robinson James A. Jr. director 852 WINTER STREET, WALTHAM MA 02451
Gerald W. Mclaughlin director, officer: Chief Executive Officer 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Richard I Eisenstadt officer: Chief Financial Officer 4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
John M Limongelli officer: SVP & General Counsel 700 PENNSYLVANIA DRIVE, EXTON PA 19341
Thomas P Mcdonnell officer: Chief Commercial Officer C/O NEOS THERAPEUTICS, INC. 2940 N. HIGHWAY 360 GRAND PRAIRIE TX 75050
Vipin K Garg officer: Chief Executive Officer 4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Dorothy Engelking officer: VP, Regulatory Affairs C/O NEOS THERAPEUTICS, INC. 2940 N. HIGHWAY 360 GRAND PRAIRIE TX 75050
Paul R Edick director C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010
Juergen Martens officer: Chief Tech/Operations Officer 28903 NORTH AVENUE PAINE, VALENCIA CA 91355